期刊文献+

系统性红斑狼疮患者血清MMP-9、TI MP-1及TNF-α水平测定及意义 被引量:4

The clinical significance and serum levels of MMP-9,TIMP-1 and TNF-α in patients with systemic lupus erythematosus
暂未订购
导出
摘要 目的探讨血清MMP-9、TIMP-1和TNF-α在系统性红斑狼疮(SLE)患者中的水平及临床意义。方法采用ELISA双抗夹心法测定血清MMP-9、TIMP-1和TNF-α水平。结果40例SLE患者血清MMP-9水平与对照组比较差异有统计学意义(P<0.01),血清TIMP-1水平与对照组比较差异有统计学意义(P<0.05),血清TNF-a水平在SLE患者和对照组之间差别无统计学意义。结论血清MMP-9、TIMP-1和TNF-α参与了SLE的发病机制。 Objective To discussion the clinical significance and serum levels of MMP-9, TIMP-1 and TNF-α in patients with systemic lupus erythematasus(SLE).Melhods The serum MMP-9, TIMP-1 and TNF-α were measured by sandwich ELISA in 40 patients with SLE and 30 healthy controls.Results The serum level of MMP-9 was significantly higher in patients with SLE compared with those in healthy controls ( P 〈 0.01 ) . The serum level of TIMP-1 was significantly higher in patients with SLE compared with those in healthy counrols ( P 〈0.05 ) .There was no significant differences of sennn TNF-a level between patients with SLE and healthy controls. Conclusion MMP-9, TIMP-1 and TNF-α may he involved in the pathogenesis of SLE.
出处 《四川医学》 CAS 2009年第1期127-129,共3页 Sichuan Medical Journal
关键词 系统性红斑狼疮 基质金属蛋白酶-9 金属蛋白酶组织抑制剂-1 肿瘤坏死因子 systemic lupus erythematesus matrix metalloproteinase-9 tissue inhibitor of raetalloproteinase- 1 tumor necrosis factor
  • 相关文献

参考文献8

  • 1Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function and biochemistry [J]. Circulation Research, 2003, 92:827 - 839
  • 2Mawrin C, Brunn A, Rocken C, et al. Peripheral neuropathy in systemic lupus erythematosus pathomorphological features and distribution pattern of matrix metalloproteinases [ J]. Acta Neuropathol (Berl), 2003, 105 : 365 - 372
  • 3Opdenakker G. Van den Steen PE Gelatinase B: a tuner and amplifier of immune functions[J] .Trends in Immunology, 2001,22:571 -579
  • 4Faber-Elmann A, Sthoeger Z, Tchemiack A, et al. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus[ J]. Clin Exp Immunol, 2002, 127 : 393 - 398
  • 5Robak E, Wierzbowska A, Chmiela M, et al. Circulating total and active metalioproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus[J]. Mediators Inflamm,2006,1:17898
  • 6刘暘,郑敏,殷文浩,鲍彰.血清基质金属蛋白酶-9检测与系统性红斑狼疮活动性的关系[J].中华风湿病学杂志,2004,8(4):220-222. 被引量:4
  • 7黄玉成,李冬芹,王春燕,尹光文,王许娜.血清基质金属蛋白酶-3、-9的检测及其与系统性红斑狼疮活动性的关系[J].临床皮肤科杂志,2007,36(9):556-558. 被引量:8
  • 8Vaday GG, Hershkoviz R, Rahat MA, et al.Fibronectin bound TNF-alpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis[ J] .Leukoc Biol,2000,68:737- 747

二级参考文献14

  • 1American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus.Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum,1999,42:1785-1796.
  • 2Bombardier C,Gladman DD,Urouritz MB,et al. Derivation of the SLEDAI,disease activity index for lupus patients.The Cmmittee on rognosis Studies in SLE.Arthritis Rheum, 1992,35:630-640.
  • 3Sato Y,Fujimoto S,Hamai K,et al. Serial alterations of glomerular matrix-degrading metalloproteinase activity in anti-thymocyteinduced glomerulonephritis in rats.Nephron,1998,78:195-200.
  • 4Faber-Elmann A,Eilat E,Zinger H,et al.A peptide based on antiDNA autoantibody down regulates matrix metalloproteinase. ClinImmunol,2002,105:223 -232.
  • 5Sharif M,Salisbury C,Taylor DJ,et al.Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in realy rheumatoid arthritis. Arthritis Rheum,1998,41:1203-1209.
  • 6Kotajima L,Aotsuka S,Fujimani M,et al.Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis[J].Clin Exp Rheumatol,1998,16(4):409-415.
  • 7Zucker S,Mian N,Drews M,et al.Increased serum stromelysin-1 levels in systemic lupus erythematosus:lack of correlation with disease activity[J].J Rheumatol,1999,26(1):78-80.
  • 8Zucker S,Hymowitz M,Conner C,et al.Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues.Clinical and experimental applications[J].Ann NY Acad Sci,1999,878:212-227.
  • 9Faber-Elmann A,Sthoeger Z,Tcherniack A,et al.Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus[J].Clin Exp Immunol,2002,127(2):393-398.
  • 10Ainiala H,Hietaharju A,Dastidar P,et al.Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities[J].Arthritis Rheum,2004,50(3):858-865.

共引文献10

同被引文献62

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部